Hence, the limited expression of the proper CKRs, such as CCR7 and CXCR5, and key adhesion molecules, such as CD62L, may limit the contribution of NK cells in currently used treatment regimens for lymphoma as many of these are based on therapeutic antibodies, including the anti-CD20 antibody rituximab. This evidence concerns the gene CXCR5 and lymphoma.